Overcoming Patient Barriers in Glycemic Control: Clinical Advances in Combination GLP-1 and Insulin Therapy
This Continuing Education activity is supported by an educational grant from sanofi-aventis U.S.
This activity is supported by an educational grant from
sanofi-aventis U.S.
Faculty
Eden Miller, DO
High Lakes Health Care Executive Director and Co-founder,
Diabetes Nation
Bend, Oregon
Jennifer Costello, PharmD, BCPS, BC-ADM
Assistant Director of Clinical Services for the Pharmacy Department
PGY-1 Residency Program Director
Saint Barnabas Medical Center
Livingston, New Jersey
Educational Objectives
After completing this continuing education program, the participant will be able to:
- Examine the glycemic control treatment gap in patients with type 2 diabetes and the factors that contribute to poor glycemic control
- Explain the use of combination regimens as initial treatment of type 2 diabetes to improve glycemic control
- Analyze the efficacy and safety of prandial insulin and glucagon-like peptide-1 (GLP-1) receptor agonists (both short-and long-acting) in combination with basal insulin, including the use of injectable coformulations
- Explore the role of the pharmacist in collaborating with clinicians and educating patients about GLP-1 agonists in combination with basal insulin and measures taken to decrease diabetic complications and promote adherence
Target audience: Retail P
harmacists
Type of activity: Application
Release date: June 12, 2016
Expiration date: June 12, 2017
Estimated time to complete activity: 2.0 hours
Fee: Free
Pharmacy Times Continuing Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 2.0 contact hours (0.2 CEUs) under the ACPE universal activity number 0290-0000-16-079-H01-P. The activity is available for CE credit through June 12, 2017.
